Botulinum Toxin for Urinary Tract Disease

Botulinum toxin was approved by the Food and Drug Administration in 2011 for neurogenic bladder and in 2013 for idiopathic overactive bladder (OAB). In this Special Issue, we address the question of where we stand with this therapy a decade later. Has it prevailed and been proven useful? Which techn...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
स्वरूप: Online
भाषा:अंग्रेज़ी
प्रकाशित: MDPI - Multidisciplinary Digital Publishing Institute 2026
विषय:
ऑनलाइन पहुंच:ONIX_20260416T142754_9783725863389_7
टैग: टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
_version_ 1869515576633720832
collection Directory of Open Access Books
description Botulinum toxin was approved by the Food and Drug Administration in 2011 for neurogenic bladder and in 2013 for idiopathic overactive bladder (OAB). In this Special Issue, we address the question of where we stand with this therapy a decade later. Has it prevailed and been proven useful? Which techniques have become established, and how were they optimized? Are more practical ways of distribution on the way? What acceptance problems or obstacles to long-term use might exist among patients or doctors? What are the risks? Has the therapy gained a foothold in the outpatient sector?
format Online
id doab-20.500.12854ir-175252
institution Directory of Open Access Books
language eng
publishDate 2026
publishDateRange 2026
publishDateSort 2026
publisher MDPI - Multidisciplinary Digital Publishing Institute
publisherStr MDPI - Multidisciplinary Digital Publishing Institute
record_format ojs
spelling doab-20.500.12854ir-1752522026-04-16T19:54:04Z Botulinum Toxin for Urinary Tract Disease Schulte-Baukloh, Heinrich Botulinum toxin Sensory Bladder Nerve Mechanosensitivity Overactive bladder Detrusor overactivity Neurogenic bladder dysfunction Detrusor wall thickness Injection Female urinary incontinence Urgency urinary incontinence Bladder botulinum toxin Botox® Adverse effects Neurogenic detrusor overactivity Idiopathic overactive bladder OnabotulinumtoxinA Meta-analysis BotulinumtoxinA detrusor injection Needle thickness Pain Local anesthesia Underactive bladder Chronic urine retention Botulinum toxin A Transvaginal ultrasound guidance External sphincter injection Transurethral incision of the bladder neck Neurogenic bladder Anxiety General anesthesia Urge incontinence Botox Procedure considerations Minimally invasive therapy OnabotulinumtoxinA intravesical injection Urge urinary incontinence Idiopathic Injection paradigm Trigone Suburothelial N A thema EDItEUR::M Medicine and Nursing Botulinum toxin was approved by the Food and Drug Administration in 2011 for neurogenic bladder and in 2013 for idiopathic overactive bladder (OAB). In this Special Issue, we address the question of where we stand with this therapy a decade later. Has it prevailed and been proven useful? Which techniques have become established, and how were they optimized? Are more practical ways of distribution on the way? What acceptance problems or obstacles to long-term use might exist among patients or doctors? What are the risks? Has the therapy gained a foothold in the outpatient sector? 2026-04-16T19:53:56Z 2026-04-16T19:53:56Z 2026 book ONIX_20260416T142754_9783725863389_7 9783725863389 9783725863396 https://directory.doabooks.org/handle/20.500.12854/175252 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/ https://mdpi.com/books/pdfview/book/12164 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-6339-6 10.3390/books978-3-7258-6339-6 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725863389 9783725863396 138 CH open access
spellingShingle Botulinum toxin
Sensory
Bladder
Nerve
Mechanosensitivity
Overactive bladder
Detrusor overactivity
Neurogenic bladder dysfunction
Detrusor wall thickness
Injection
Female urinary incontinence
Urgency urinary incontinence
Bladder botulinum toxin
Botox®
Adverse effects
Neurogenic detrusor overactivity
Idiopathic overactive bladder
OnabotulinumtoxinA
Meta-analysis
BotulinumtoxinA detrusor injection
Needle thickness
Pain
Local anesthesia
Underactive bladder
Chronic urine retention
Botulinum toxin A
Transvaginal ultrasound guidance
External sphincter injection
Transurethral incision of the bladder neck
Neurogenic bladder
Anxiety
General anesthesia
Urge incontinence
Botox
Procedure considerations
Minimally invasive therapy
OnabotulinumtoxinA intravesical injection
Urge urinary incontinence
Idiopathic
Injection paradigm
Trigone
Suburothelial
N
A
thema EDItEUR::M Medicine and Nursing
Botulinum Toxin for Urinary Tract Disease
title Botulinum Toxin for Urinary Tract Disease
title_full Botulinum Toxin for Urinary Tract Disease
title_fullStr Botulinum Toxin for Urinary Tract Disease
title_full_unstemmed Botulinum Toxin for Urinary Tract Disease
title_short Botulinum Toxin for Urinary Tract Disease
title_sort botulinum toxin for urinary tract disease
topic Botulinum toxin
Sensory
Bladder
Nerve
Mechanosensitivity
Overactive bladder
Detrusor overactivity
Neurogenic bladder dysfunction
Detrusor wall thickness
Injection
Female urinary incontinence
Urgency urinary incontinence
Bladder botulinum toxin
Botox®
Adverse effects
Neurogenic detrusor overactivity
Idiopathic overactive bladder
OnabotulinumtoxinA
Meta-analysis
BotulinumtoxinA detrusor injection
Needle thickness
Pain
Local anesthesia
Underactive bladder
Chronic urine retention
Botulinum toxin A
Transvaginal ultrasound guidance
External sphincter injection
Transurethral incision of the bladder neck
Neurogenic bladder
Anxiety
General anesthesia
Urge incontinence
Botox
Procedure considerations
Minimally invasive therapy
OnabotulinumtoxinA intravesical injection
Urge urinary incontinence
Idiopathic
Injection paradigm
Trigone
Suburothelial
N
A
thema EDItEUR::M Medicine and Nursing
topic_facet Botulinum toxin
Sensory
Bladder
Nerve
Mechanosensitivity
Overactive bladder
Detrusor overactivity
Neurogenic bladder dysfunction
Detrusor wall thickness
Injection
Female urinary incontinence
Urgency urinary incontinence
Bladder botulinum toxin
Botox®
Adverse effects
Neurogenic detrusor overactivity
Idiopathic overactive bladder
OnabotulinumtoxinA
Meta-analysis
BotulinumtoxinA detrusor injection
Needle thickness
Pain
Local anesthesia
Underactive bladder
Chronic urine retention
Botulinum toxin A
Transvaginal ultrasound guidance
External sphincter injection
Transurethral incision of the bladder neck
Neurogenic bladder
Anxiety
General anesthesia
Urge incontinence
Botox
Procedure considerations
Minimally invasive therapy
OnabotulinumtoxinA intravesical injection
Urge urinary incontinence
Idiopathic
Injection paradigm
Trigone
Suburothelial
N
A
thema EDItEUR::M Medicine and Nursing
url ONIX_20260416T142754_9783725863389_7